Volume 13 Supplement 1

Melanoma Bridge 2014: meeting abstracts

Open Access

αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations

  • Giacoma De Tullio1,
  • Sabino Strippoli2,
  • Rosa Angarano1,
  • Vincenza De Fazio1,
  • Nicola Sgherza1,
  • Antonio Negri1,
  • Anna Albano2,
  • Pasquale Iacopino1, 3,
  • Attilio Guarini1 and
  • Michele Guida2
Journal of Translational Medicine201513(Suppl 1):O10

https://doi.org/10.1186/1479-5876-13-S1-O10

Published: 15 January 2015

Background

The knowledge of the immune system role on melanoma has accelerated the translation of key advancements into medical breakthroughs like ipilimumab, an anti-CTLA4 immunomodulating antibody. Ipilimumab works amazingly well only in a limited number of patients and its effects on T-cell subpopulations as well as on immune response remains to be elucidated. Recently, it was described a new subset of immunomodulating T-cells, known as Double-negative T-cells (DNTs) expressing either αβ or γδ T-cell receptors (TCR) but lacking CD4,CD8,CD56. The DNTs contribute specifically to anti-tumor immunity since involved in immune regulation and tolerance acting as regulatory T-cells (Treg) and/or cytotoxic T-cells and they contribute to in vivo anti-melanoma immunity as previously reported [15]. However no data are available on their frequency in melanoma, as well as the effects of ipilimimumab on DNTs functional attitude in immunomodulation and on modulating their expression during the therapy. We aimed to evaluate the modulation of DNT frequency in Metastatic Melanoma (MM) patients treated with ipilimumab during the therapy in order to explore their potential role on clinical outcome and therapy response.

Patients and methods

We carried out flow cytometric studies and statistical analyses on data of frequency of DNTs from 136 individuals, which included 16 healthy donors,30 MM patients who received ipilimumab as second line therapy, and 90 lymphoma patients. To evaluate the modulation of DNT during ipilimumab therapy we collected peripheral blood of MM subset at three time points: 1. Before start of therapy, 2. Before the 3th ipilimumab infusion, 3. After 2 months from the end of therapy. All patients provided their informed consent in accordance with the Declaration of Helsinki.

Results

We observed a significant decrease (p =0.001) of circulating αβ-DNT frequency in MM (13.49cells/ul±5.4) as compared with healthy controls (31.3cells/ul ± 3.4) and more interestingly when compared with Lymphoma patients (p=0.001) (fig.1). Furthermore, αβ-DNTs was significantly increased (p=0.048) in MM patients with ECOG performance status ≤1 as compared with >1 (fig.2). Finally, despite a low cluster was collected until the last time point sample, we observed a trend of significant increasing (p=0.083) in αβ-DNTs during the ipilimumab treatment (fig.3).
Fig 1

Circulating αβ-DNT frequency in Melanoma patients as compared with healthy controls and Lymphoma patients P=0,048

Fig 2

Circulating αβ-DNT frequency in Melanoma patients based of ECOG performance status.

Fig 3

Circulating αβ-DNT frequency in Melanoma patients during the Ipilimumab treatment

Conclusions

This is the first report on evaluation of αβ-DNTs in MM patients and their modulation by an immunomodulating drug such as ipilimumab. Our preliminary data suggested a lower frequency of αβ-DNTs and a worse immunological impairment in MM compared to healthy and lymphoma subject as well as a trend of increasing of this T-cell population during the therapy. These results, supported by future studies, could estabilish the role of DNTs in MM patients and the significance of their increase during ipilimumab therapy.

Authors’ Affiliations

(1)
Hematology Unit, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”
(2)
Medical Oncology Department National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”
(3)
Clinical Institute “Prof. R. De Blasi”

References

  1. Golden EB, Frances D, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC: Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology. 2014, 3: e28518-10.4161/onci.28518.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Formenti SC, Demaria S: Combining radiotherapy and cancer immunotherapy: a paradigm shift. Journal of the National Cancer Institute. 2013, 105 (4): 256-265. 10.1093/jnci/djs629.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005, 11 (2): 728-734.PubMedGoogle Scholar
  4. Postow MA1, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012, 366: 925-931. 10.1056/NEJMoa1112824.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC: An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer immunology research. 2013, 1 (6): 365-372. 10.1158/2326-6066.CIR-13-0115.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC: Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004, 58 (3): 862-870. 10.1016/j.ijrobp.2003.09.012.View ArticlePubMedGoogle Scholar
  7. Formenti SC, Demaria S: Systemic effects of local radiotherapy. Lancet Oncol. 2009, 10 (7): 718-726. 10.1016/S1470-2045(09)70082-8.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, Liu M, Formenti SC, Dustin ML, Demaria S: Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012, 122 (10): 3718-3730. 10.1172/JCI61931.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002, 419 (6908): 734-738. 10.1038/nature01112.View ArticlePubMedGoogle Scholar
  10. Jinushi M, Hodi FS, Dranoff G: Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2008, 103 (24): 9190-9195.View ArticleGoogle Scholar
  11. Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005, 436 (7054): 1186-1190. 10.1038/nature03884.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© De Tullio et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement